# A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)

> **NCT00279747** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 226 (—)

## Conditions studied

- Arthritis, Juvenile Rheumatoid

## Interventions

- **DRUG:** meloxicam 0.25 mg/kg
- **DRUG:** meloxicam 0.125 mg/kg
- **DRUG:** naproxen 10 mg/kg

## Key facts

- **NCT ID:** NCT00279747
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09
- **Primary completion:** 2003-01
- **Final completion:** 2003-01
- **Target enrollment:** 226 (—)
- **Last updated:** 2013-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00279747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00279747, "A One Year Double-blind Trial to Investigate the Efficacy and Safety of Meloxicam Oral Suspension in Juvenile Rheumatoid Arthritis (JRA/JIA)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00279747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*